[144] Arcus Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Arcus Biosciences (RCUS) Form 144 summary: The notice reports a proposed sale of 2,831 common shares through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $36,350.04. The shares were acquired as restricted stock units on 12/15/2024 and the filing shows the acquisition and payment date as 12/15/2024. The form also discloses a prior sale during the past three months: a 10b5-1 sale by Alexander Azoy of 1,579 shares on 09/05/2025 for gross proceeds of $18,758.05. The filer certifies they are not aware of undisclosed material adverse information and notes Rule 10b5-1 plan considerations where applicable.

Insights

Securities Analyst

TL;DR: Insider sale of 2,831 RSU-derived shares valued at ~$36k; disclosed under Form 144, appears routine and not large.

The filing shows a proposed sale of restricted stock unit shares acquired on 12/15/2024. Execution is through a broker on 09/29/2025, with a recent related 10b5-1 sale of 1,579 shares on 09/05/2025. For investors, these transactions are documented disposals by an insider or related party rather than company-level corporate actions. The sizes and proceeds disclosed are explicit and should be compared to outstanding shares and typical insider activity to assess significance.

Corporate Governance Expert

TL;DR: Form 144 properly discloses proposed sale and RSU origin; includes required insider certification about material nonpublic information.

The notice includes required details: class of securities, broker, acquisition date and nature (RSUs), and prior sales in the past three months. It also contains the representation that the seller does not possess undisclosed material adverse information and references Rule 10b5-1 plan adoption where relevant. Filing completeness supports regulatory compliance for an insider sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2831	36350.04	106430976	09/29/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/15/2024	Restricted Stock Units	Issuer			2831	12/15/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ALEXANDER AZOY 3928 Point Eden Way Hayward CA 94545	Common	09/05/2025	1579	18758.05

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Arcus Biosciences (RCUS) disclose?

The form discloses a proposed sale of 2,831 common shares via Morgan Stanley Smith Barney on 09/29/2025 valued at $36,350.04.

How were the shares being sold acquired according to the filing?

The shares were acquired as restricted stock units on 12/15/2024, with the filing listing the acquisition and payment date as 12/15/2024.

Were there any recent related sales reported in the past three months?

Yes. A 10b5-1 sale by Alexander Azoy of 1,579 common shares on 09/05/2025 generated gross proceeds of $18,758.05.

Through which broker will the proposed sale be executed?

The proposed sale is listed to be executed through Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York, NY.

Does the Form 144 include any statement about material nonpublic information?

Yes. The person for whose account the securities will be sold represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.